ResApp Health (ASX:RAP) Executive Director Brian Leedman:
ResApp Health was listed on the ASX in July of 2015, and we’re the world’s first digital diagnostic company on a smartphone. So what we do is we take signatures of the sound of a cough. And we marry that to a database of algorithms that analyse the sound of that cough and say that it’s a pneumatic cough, or a bronchial cough, or an asthmatic cough.
We felt after the last study that we needed to bolster our scientific Board, with some greater medical experience. Dr Currie is a top cardiologist, but more importantly, he’s had experience working and training in the hospitals that we’re actually conducting these studies in. So Dr Currie brings a wealth of experience, he’s also a shareholder of the company, a long-term shareholder.
By the middle of next year, we’ll be talking about our excellent results from the clinical study, and the FDA submission will shortly follow. I would hope by the end of next year, we’ll actually get our first approval by the FDA for our technology, to then move into commercial negotiation deals of which, I’m sure there’ll be many as we’ve had tremendous inbound interest from all the end users, including the telehealth companies, to incorporate our technology into their consumer platforms.